European Primary Care Cardiovascular Society
EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.
Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.
The LIFE-CVD model can assess 10-year and lifetime CVD risk and life-years gained free from CVD and the effect of interventions in apparently healthy people.
EPCCS 2019 Professor Peter van der Meer & Monika Hollander consider new recommendations in the latest ESC Guidelines on diagnosis and treatment of patients with HF, and the role GPs may play in this process.
The PCP-HF score provides sex- and race-specific estimates of 10-year risk of incident HF, based on risk factor information readily available in primary care setting.
EAS 2019 By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk. With poll
EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.
EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.
EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality
EAS 2019 A fixed combination of bempedoic acid and ezetimibe lowered LDL-c at 12 weeks more than with the individual components, in high-risk patients not at LDL-c goal.
EAS 2019 Børge Nordestgaard made the case for remnant cholesterol and TG, because of the known links of high levels with heart attack, ischemic stroke and death, more so than high LDL-c.
ESC HF 2019 In this debate, Douglas Packer and John Cleland took opposite sides of the statement that all patients with atrial fibrillation and heart failure should receive ablation. With poll.
